Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Corgentech analgesic NDA tabbed for mid-’06

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Corgentech plans to submit an NDA in mid-2006 for its needleless lidocaine injection system ALGRX 3268, the firm says Feb. 21. The product is targeted at children undergoing medical procedures requiring venipunctures and intravenous line placements. "With an onset of action of one to three minutes, ALGRX 3268 provides a unique fast-acting, local anesthetic for reducing pain associated with peripheral venous access and I.V. insertion procedures in children," the company says. Corgentech estimates approximately 18 mil. relevant procedures occur each year. 3268 is the first of three pain relievers Corgentech plans on filing...

You may also be interested in...

American Injectables $10m Investment Bolsters Domestic Production

American Injectables plans to build up its US-based manufacturing after securing a commitment for $10m of ‘Series A’ financing from New Rhein Healthcare Investors, which it will use to scale up production and launch several generic parenteral products.

EMA Consults On Using Registry Studies As RWE Source

A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.

Italy: Pharma May Have To Disclose Confidential Info Under New Pricing Rules

Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts